AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Discover which Aristocrats ETF delivers the best value by fee and why cost matters for long-term returns. Learn quick tips to compare expense ratios and pick the right fund.
25,968 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Tech stocks tumble second day as investors require evidence that AI investments will pay off, dragging Nvidia, Alphab...
Hype around SpaceX drew many investors who bought after the IPO. As gains fade, you need a plan. This guide breaks do...
A top executive recently moved a sizable block of Impinj stock. This article unpacks why insider sales happen, how to...
A notable price dip in SpaceX shares has investors wondering if this is a turning point. This guide explains how to a...
A New York Supreme Court filing brings a human claimant into a case over billions in dormant Bitcoin. The move could ...
CryptoQuant data shows the altcoin market reaches extreme weakness, with 40% of tokens trading near all-time lows as ...
Shiba Inu wallets rise to an all-time high even as SHIB's price continues to slide, underscoring a split between on-c...
TSMC is set to release Q2 results on July 16, 2026 as investors weigh a record profit jump and the path forward for A...
Mark Cuban is reviving the debate over wage inequality by urging companies to grant stock to every worker. His pitch ...
A once-hot stock that rode the COVID surge now sits far from its peak. This piece breaks down how wall street erases ...
CrowdStrike accelerates an acquisition push as Palo Alto Networks doubles down on platform strategy. Both leaders rep...